These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 16250928)

  • 1. Sequencing bortezomib with chemotherapy and targeted agents.
    Adjei AA
    Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S56-8. PubMed ID: 16250928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib-based combinations in the treatment of non-small-cell lung cancer.
    Davies AM; Lara PN; Mack PC; Gumerlock PH; Bold RJ; Gandara DR
    Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S59-63. PubMed ID: 16250929
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Proteasome inhibitor].
    Yamamura M; Hirai T; Yamaguchi Y
    Nihon Rinsho; 2010 Jun; 68(6):1079-84. PubMed ID: 20535959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential role of bortezomib in combination with chemotherapy and radiation in non-small-cell lung cancer.
    Edelman MJ
    Clin Lung Cancer; 2005 Oct; 7 Suppl 2():S64-6. PubMed ID: 16250930
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proteasome: an emerging target for cancer therapy.
    Zavrski I; Jakob C; Schmid P; Krebbel H; Kaiser M; Fleissner C; Rosche M; Possinger K; Sezer O
    Anticancer Drugs; 2005 Jun; 16(5):475-81. PubMed ID: 15846112
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential of proteasome inhibitors in cancer therapy.
    Sterz J; von Metzler I; Hahne JC; Lamottke B; Rademacher J; Heider U; Terpos E; Sezer O
    Expert Opin Investig Drugs; 2008 Jun; 17(6):879-95. PubMed ID: 18491989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The proteasome: a novel target for anticancer therapy.
    Montagut C; Rovira A; Albanell J
    Clin Transl Oncol; 2006 May; 8(5):313-7. PubMed ID: 16760005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy.
    Lara PN; Davies AM; Mack PC; Mortenson MM; Bold RJ; Gumerlock PH; Gandara DR
    Semin Oncol; 2004 Feb; 31(1 Suppl 1):40-6. PubMed ID: 14981579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib for multiple myeloma.
    Popat R; Joel S; Oakervee H; Cavenagh J
    Expert Opin Pharmacother; 2006 Jul; 7(10):1337-46. PubMed ID: 16805719
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the proteasome inhibitor bortezomib alone and in combination with chemotherapy in the A549 non-small-cell lung cancer cell line.
    Mortenson MM; Schlieman MG; Virudachalam S; Bold RJ
    Cancer Chemother Pharmacol; 2004 Oct; 54(4):343-53. PubMed ID: 15197486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer.
    Denlinger CE; Keller MD; Mayo MW; Broad RM; Jones DR
    J Thorac Cardiovasc Surg; 2004 Apr; 127(4):1078-86. PubMed ID: 15052205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bortezomib in combination with other therapies for the treatment of multiple myeloma.
    Orlowski RZ
    J Natl Compr Canc Netw; 2004 Nov; 2 Suppl 4():S16-20. PubMed ID: 19791424
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery, Development, and clinical applications of bortezomib.
    Jung L; Holle L; Dalton WS
    Oncology (Williston Park); 2004 Dec; 18(14 Suppl 11):4-13. PubMed ID: 15688597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potential for proteasome inhibition in the treatment of cancer.
    Adams J
    Drug Discov Today; 2003 Apr; 8(7):307-15. PubMed ID: 12654543
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The proteasome inhibitor bortezomib targets cell cycle and apoptosis and acts synergistically in a sequence-dependent way with chemotherapeutic agents in mantle cell lymphoma.
    Hutter G; Rieken M; Pastore A; Weigert O; Zimmermann Y; Weinkauf M; Hiddemann W; Dreyling M
    Ann Hematol; 2012 Jun; 91(6):847-56. PubMed ID: 22231280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integration of the proteasome inhibitor PS-341 (Velcade) into the therapeutic approach to lung cancer.
    Mack PC; Davies AM; Lara PN; Gumerlock PH; Gandara DR
    Lung Cancer; 2003 Aug; 41 Suppl 1():S89-96. PubMed ID: 12867067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies.
    Ludwig H; Khayat D; Giaccone G; Facon T
    Cancer; 2005 Nov; 104(9):1794-807. PubMed ID: 16178003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Proteasome inhibitors].
    Saeki Y; Fukunaga K; Tanaka K
    Nihon Rinsho; 2010 Oct; 68(10):1818-22. PubMed ID: 20954323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the ubiquitin-proteasome pathway in cancer therapy.
    Ishii Y; Waxman S; Germain D
    Anticancer Agents Med Chem; 2007 May; 7(3):359-65. PubMed ID: 17504161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of proteasome inhibition in the treatment of lung cancer.
    Schenkein DP
    Clin Lung Cancer; 2004 Dec; 6 Suppl 2():S89-96. PubMed ID: 15638966
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.